Report Library
All Reports
2015 Breast Cancer Pulse #3
June 12, 2015
This 5-question pulse of 25 oncologists practicing in the United States is a follow-up on two pulses (available here and here) performed in May 2015.
This pulse incorporates updated data presented at the 2015 ASCO annual meeting from the PALOMA3 trial of palbociclib for the 2nd-line
treatment of HR+/HER2- advanced breast cancer and from the ExteNET trial of neratinib for the extended adjuvant treatment of HER2+,
Stage 2 or 3 breast cancer.
The following drugs are discussed in this pulse:
To purchase this survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
The following drugs are discussed in this pulse:
- Ibrance (neratinib, PFE)
- Afinitor (everolimus, NVS)
- Neratinib (PBYI)
To purchase this survey, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Breast Cancer |
Additional Resources: